All In Biotech

Drug Trial Radar · NCT01617772

Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis

Comparison the Effectiveness of L-Carnitine With Atorvastatin in Non-Alcoholic Steatohepatitis (NASH)

Last checked: Nov 19, 2026Latest source record: May 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

440

Planned (sponsor's estimate)

Start

Jan 1, 2016

Primary completion

Oct 2019

Study completion Dec 2019

Sponsor

Lead sponsor
Tehran University of Medical SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 12, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the present study was to compare the effects of simvastatin and L-carnitine coadministration versus simvastatin, L-Carnitine monotherapy on liver transaminases and liver elasticity in NASH patients.

Conditions

  • Non-alcoholic Steatohepatitis

Interventions

  • AtorvastatinDrug

    Atorvastatin 20 mg

  • L-CarnitineDrug

    1000mg L-carnitine

  • PlaceboDrug

    Identically looking placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. improvement in liver stiffnessTime frame: 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Masoud Clinic

    Tehran, Iran · Recruiting

  • Pars Cohort Center

    Shiraz, Fars, Iran · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.